SCHEMBL6816305

SCHEMBL6816305

CC(=O)N[C@@H]1[C@H](OC[C@H]2O[C@H](O)[C@H](O)[C@@H](O)[C@H]2O)O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@@H]1O

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 6/20 0.68
▸ LGALS8 O00214 1/20 0.68
▸ LGALS4 P56470 1/20 0.68
▸ MAPK1 P28482 2/20 0.52
▸ AMY2A P04746 3/20 0.50
▸ LGALS1 P09382 1/20 0.50
▸ LGALS7; LGALS7B P47929 1/20 0.50
▸ CD69 Q07108 1/20 0.49
▸ CHIA Q9BZP6 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ THRB P10828 1/20 0.48
▸ LGALS9 O00182 1/20 0.47
▸ HPSE Q9Y251 2/20 0.46
▸ CD209 Q9NNX6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5525281 1.00 LGALS3 (0.68) LGALS3LGALS8LGALS4MAPK1AMY2A
SCHEMBL7717427 0.97 LGALS3 (0.64) LGALS3LGALS8LGALS4MAPK1AMY2A
SCHEMBL6122661 0.97 LGALS3 (0.64) LGALS3LGALS8LGALS4MAPK1AMY2A
SCHEMBL31694310 0.97 LGALS3 (0.64) LGALS3LGALS8LGALS4MAPK1AMY2A
SCHEMBL7717429 0.97 LGALS3 (0.64) LGALS3LGALS8LGALS4MAPK1AMY2A
SCHEMBL6471615 0.97 LGALS3 (0.64) LGALS3LGALS8LGALS4MAPK1AMY2A
SCHEMBL30970822 0.96 LGALS3 (0.63) LGALS3LGALS8LGALS4MAPK1AMY2A
SCHEMBL31701570 0.96 LGALS3 (0.63) LGALS3LGALS8LGALS4MAPK1AMY2A
SCHEMBL13855946 0.96 LGALS3 (0.66) LGALS3LGALS8LGALS4MAPK1AMY2A
SCHEMBL30185411 0.96 LGALS3 (0.66) LGALS3LGALS8LGALS4MAPK1AMY2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0475160-B2 Preparation for drug application in minute droplet form IDEA AG (DE) 2004-07-14 — — EP disclosed
US-20020142046-A1 Protein particles for therapeutic and diagnostic use YEN, RICHARD C.K. 2002-10-03 — — US disclosed
US-6391343-B1 PARTICLE COMPRISING FIBRINOGEN BOUND ON SURFACE OF ALBUMIN MATRIX, CAPABLE OF CO-AGGREGATION WITH PLATELETS, AND OF AGGREGATION IN SOLUTION CONTAINING SOLUBLE FIBRINOGEN AT CONCENTRATION NOT CAPABLE OF CLOT FORMATION BY ITSELF HEMOSPHERE, INC. 2002-05-21 — — US disclosed
US-5945033-A ALBUMIN, HEMOGLOBIN MIXTURE; STABILITY HEMOSPHERE, INC. (US) 1999-08-31 — — US disclosed
US-5725804-A ALBUMIN PARTICLES STABLE TO RESOLUBILIZATION, POLYOXYETHYLENE GLYCOL, ALCOHOL HEMOSPHERE, INC. (US) 1998-03-10 — — US disclosed
EP-0649427-B1 SEQUENTIAL REMOVAL OF MONOSACCHARIDES FROM THE REDUCING END OF OLIGOSACCHARIDES AND USES THEREOF BIOMEMBRANE INST (US) 1998-01-28 — — EP disclosed
US-5616311-A AQUEOUS ALBUMIN SUSPENSION STABILIZED BY HEMOGLOBIN PARTICLES HEMOSPHERE, INC. (US) 1997-04-01 — — US disclosed
EP-0475160-B1 Preparation for drug application in minute droplet form IDEA AG (DE) 1996-02-14 — — EP disclosed
US-5403927-A Sequential removal of monosaccharides from the reducing end of oligosaccharides and uses thereof THE BIOMEMBRANE INSTITUTE (US) 1995-04-04 — — US disclosed
EP-0475160-A1 Preparation for drug application in minute droplet form Cevc, Gregor, Prof. Dr. (DE) 1992-03-18 — — EP disclosed
Send feedback